---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-390652"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-09-14T20:30:17+00:00"
generated_at: "2026-09-14T20:33:41.525010+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics sells A-T assets to Ayma for $450K; President Ryan departs

## Summary
- Completed sale of Quince SpA, AIDE IP, and eDSP machines to Ayma Therapeutics for $450,000 cash on Sept 8, 2026.
- Sale includes ~55 AIDE/eDSP machines: ~20 at Italian facilities, ~35 at clinical trial sites.
- President Charles Ryan separated Sept 8, 2026; severance of $1,014,489.04 under Separation Agreement.
- Pro forma financials assume sale effective Jan 1, 2025 for operations; balance sheet as of June 30, 2026.

## SEC filing metadata
- accession: 0001193125-26-390652
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-09-14T20:30:17+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/0001193125-26-390652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/qncx-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-390652
- JSON: https://secwatch.observer/filing/0001193125-26-390652.json
- Plain text: https://secwatch.observer/filing/0001193125-26-390652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.